Improved survival when venetoclax, an oral inhibitor of BCL-2, is added to azacitidine or low-dose cytarabine in adults with newly diagnosed AML [54,55,56] has highlighted the importance of anti-apoptotic BCL-2 family proteins for the survival and chemoresistance of AML cells. Here, BCL2 is linked to acute myeloid leukemia.